Cargando…

Potential of a glucagon‐like peptide‐1 receptor/glucose‐dependent insulinotropic polypeptide receptor/glucagon receptor triagonist for the treatment of obesity and type 2 diabetes

Triagonists of GLP‐1R/ GIPR /GCGR, including SAR441255, bind to each receptor and induce specific effects through each receptor signaling pathway, thus result in weight loss and glycemic control in obese T2D animal models.[Image: see text]

Detalles Bibliográficos
Autores principales:	Araki, Eiichi, Sakaguchi, Masaji, Fukuda, Kazuki, Kondo, Tatsuya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9720191/ https://www.ncbi.nlm.nih.gov/pubmed/36039895 http://dx.doi.org/10.1111/jdi.13896

Ejemplares similares

The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect
por: Fisman, Enrique Z., et al.
Publicado: (2021)

A comparative transcriptomic analysis of Glucagon-like peptide-1 receptor- and Glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus
por: Smith, Christopher, et al.
Publicado: (2022)

Nephroprotective Properties of the Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) Receptor Agonists
por: Bulum, Tomislav
Publicado: (2022)

Mechanisms underlying glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 secretion
por: Reimann, Frank, et al.
Publicado: (2016)

Carbohydrate‐induced secretion of glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1
por: Seino, Yusuke, et al.
Publicado: (2016)

Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes
por: Capozzi, Megan E, et al.
Publicado: (2018)

Hepatic and Extrahepatic Insulin Clearance in Mice with Double Deletion of Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide Receptors
por: Morettini, Micaela, et al.
Publicado: (2021)

Glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1: Incretin actions beyond the pancreas
por: Seino, Yutaka, et al.
Publicado: (2013)

Glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 secretion in humans: Characteristics and regulation
por: Alsalim, Wathik, et al.
Publicado: (2022)

Differential effects of glucose‐dependent insulinotropic polypeptide receptor/glucagon‐like peptide‐1 receptor heteromerization on cell signaling when expressed in HEK‐293 cells
por: Al‐Zaid, Bashaier, et al.
Publicado: (2022)

Mineralocorticoid Receptor May Regulate Glucose Homeostasis through the Induction of Interleukin-6 and Glucagon-Like peptide-1 in Pancreatic Islets
por: Goto, Rieko, et al.
Publicado: (2019)

Effect of dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist on weight loss in subjects with obesity
por: Zaffina, Isabella, et al.
Publicado: (2023)

The Effect of Exogenous Glucose-Dependent Insulinotropic Polypeptide in Combination With Glucagon-Like Peptide-1 on Glycemia in the Critically Ill
por: Lee, Michael Y., et al.
Publicado: (2013)

The Cardiovascular Effect of Tirzepatide: A Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide Dual Agonist
por: Cho, Yun Kyung, et al.
Publicado: (2023)

Glucose-Dependent Insulinotropic Polypeptide: A Bifunctional Glucose-Dependent Regulator of Glucagon and Insulin Secretion in Humans
por: Christensen, Mikkel, et al.
Publicado: (2011)

SAT037 Glucagon-like Peptide-1 Receptor Knockout Mice Do Not Compensate For The Lack Of Incretin Action By Increasing Glucose-dependent Insulinotropic Polypeptide Secretion
por: Douglas Galsgaard, Katrine, et al.
Publicado: (2023)

Incretin concept revised: The origin of the insulinotropic function of glucagon‐like peptide‐1 – the gut, the islets or both?
por: Yabe, Daisuke, et al.
Publicado: (2017)

Emetic Response to T-2 Toxin Correspond to Secretion of Glucagon-like Peptide-(17)(–36) Amide and Glucose-Dependent Insulinotropic Polypeptide
por: Zhang, Jie, et al.
Publicado: (2022)

Glucagon-like peptide 1 and glucose-dependent insulinotropic peptide hormones and novel receptor agonists protect synapses in Alzheimer’s and Parkinson’s diseases
por: Hölscher, Christian
Publicado: (2022)

Glucagon‐like peptide‐1 receptor agonists and their effects on weight reduction
por: Shin, Shyi‐Jang
Publicado: (2012)

Evidence‐based comparison of glucagon‐like peptide receptor agonists and sodium–glucose cotransporter 2 inhibitors
por: Watada, Hirotaka
Publicado: (2019)

Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice
por: Pocai, Alessandro, et al.
Publicado: (2009)

The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 (GLP‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long‐acting GLP‐1 receptor agonists
por: Urva, Shweta, et al.
Publicado: (2020)

The Incretins and Pancreatic β-Cells: Use of Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide to Cure Type 2 Diabetes Mellitus
por: Kim, Mi-Hyun, et al.
Publicado: (2010)

Fructose induces glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1 and insulin secretion: Role of adenosine triphosphate-sensitive K(+) channels
por: Seino, Yusuke, et al.
Publicado: (2015)

Glucagon-Like Peptide 1 Receptor Agonists, Carotid Atherosclerosis, and Cardiovascular Outcomes
por: Marquis-Gravel, Guillaume, et al.
Publicado: (2021)

Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide dual receptor agonist DA-CH5 is superior to exendin-4 in protecting neurons in the 6-hydroxydopamine rat Parkinson model
por: Zhang, Ling-Yu, et al.
Publicado: (2021)

Novel dual glucagon-like peptide-1/ glucose-dependent insulinotropic polypeptide receptor agonist attenuates diabetes and myocardial injury through inhibiting hyperglycemia, inflammation and oxidative stress in rodent animals
por: Wang, Ying, et al.
Publicado: (2022)

The dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc analysis
por: Wilson, Jonathan M., et al.
Publicado: (2021)

Computational Peptide Design Cotargeting Glucagon and Glucagon-like Peptide-1 Receptors
por: Vishnoi, Shubham, et al.
Publicado: (2023)

Glucagon Receptor Signaling and Glucagon Resistance
por: Janah, Lina, et al.
Publicado: (2019)

Architecture of androgen receptor pathways amplifying glucagon-like peptide-1 insulinotropic action in male pancreatic β cells
por: Xu, Weiwei, et al.
Publicado: (2023)

Clinical Trials, Triumphs, and Tribulations of Glucagon Receptor Antagonists
por: Pearson, Mackenzie J., et al.
Publicado: (2016)

Clinical relevance of dual agonist of glucagon and glucagon‐like peptide‐1 receptors to achieve functional restoration of first‐ and second‐phase insulin secretion
por: Kimura, Tomohiko, et al.
Publicado: (2022)

Role of a Dual Glucose-Dependent Insulinotropic Peptide (GIP)/Glucagon-like Peptide-1 Receptor Agonist (Twincretin) in Glycemic Control: From Pathophysiology to Treatment
por: Pelle, Maria Chiara, et al.
Publicado: (2021)

Glucagon-Like Peptide 1 Receptor Activation and Platelet Function: Beyond Glycemic Control
por: Jia, Guanghong, et al.
Publicado: (2016)

Glucagon-like Peptide-1 Receptor Analogues for the Treatment of Obesity
por: Williams, David M, et al.
Publicado: (2022)

Molecular mechanism of an antagonistic antibody against glucose-dependent insulinotropic polypeptide receptor
por: Min, Xiaoshan, et al.
Publicado: (2020)

Structural insights into hormone recognition by the human glucose-dependent insulinotropic polypeptide receptor
por: Zhao, Fenghui, et al.
Publicado: (2021)

The Glucagonostatic and Insulinotropic Effects of Glucagon-Like Peptide 1 Contribute Equally to Its Glucose-Lowering Action
por: Hare, Kristine J., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_qscein22rp5vq3tnhbkt6qm5hs